← All trials
NCT01355458
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2011
- Primary completion
- Sep 1, 2011
- Completion date
- Dec 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 260
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GaldermaLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- Dermatology Consulting Services, High Point NCOverall official - principal investigator
- Derm Research IncorporatedOverall official - principal investigator
- Lynderm Research IncOverall official - principal investigator
- Oregon Medical Research CenterOverall official - principal investigator
- The Education & Research Foundation, Inc.Overall official - principal investigator
- Arlington Center for DermatologyOverall official - principal investigator
- Windsor DermatologyOverall official - principal investigator
- Philadelphia Institute of DermatologyOverall official - principal investigator
- Michigan Center for Skin Care ResearchOverall official - principal investigator
- GaldermaStudy chair
- InnovadermOverall official - principal investigator
- Windsor Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.